Long-term PERG monitoring of untreated and treated glaucoma suspects.


Journal

Documenta ophthalmologica. Advances in ophthalmology
ISSN: 1573-2622
Titre abrégé: Doc Ophthalmol
Pays: Netherlands
ID NLM: 0370667

Informations de publication

Date de publication:
10 2020
Historique:
received: 06 11 2019
accepted: 02 03 2020
pubmed: 11 3 2020
medline: 10 10 2020
entrez: 11 3 2020
Statut: ppublish

Résumé

To investigate long-term structural and functional progression of untreated and treated glaucoma suspects (UGS and TGS). Retrospective analysis of serial steady-state pattern electroretinogram (PERG), mean retinal nerve fiber layer thickness (RNFLT), and standard automated perimetry mean deviation (SAP-MD) in UGS (N = 20) and TGS (N = 18). Outcome measures were the rates of change (linear regression slopes) of PERG amplitude, PERG phase, mean RNFLT, and SAP-MD over 9.8 ± 1.3 years (15.6 ± 4.2 visits). The number of patients with significant (P < 0.05) progression slopes for PERG amplitude, PERG phase, RNFLT, and SAP-MD was, respectively, UGS: 5, 0, 4, 2; TGS: 8, 2, 6, 5. In UGS, outcome measures were not correlated with each other. In TGS, both PERG amplitude and RNFLT were significantly (P < 0.05) correlated with SAP-MD (R ≥ 0.58), while PERG amplitude and RNFLT were not correlated with each other (R = 0.43, P = 0.064). The rate of change of SAP-MD was predicted (P < 0.05) by a linear combination of RNFLT slope and PERG amplitude slope. Results substantiate and extend previous results showing that steady-state PERG amplitude progressively decreased over time in a proportion of glaucoma suspects, with relatively steeper slope in TGS compared to UGS. RNFLT progression also had a steeper slope in TGS compared to UGS; however, progressions of PERG amplitude and RNFLT were not significantly correlated. Both PERG progression and RNFLT progression independently contribute to prediction of visual field progression.

Identifiants

pubmed: 32152920
doi: 10.1007/s10633-020-09760-5
pii: 10.1007/s10633-020-09760-5
pmc: PMC7483546
mid: NIHMS1573864
doi:

Substances chimiques

Antihypertensive Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

149-156

Subventions

Organisme : NEI NIH HHS
ID : P30 EY014801
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY014957
Pays : United States
Organisme : NEI NIH HHS
ID : RO1 EY014957
Pays : United States

Références

Ophthalmology. 2018 Nov;125(11):1817-1827
pubmed: 30322450
J Glaucoma. 2015 Apr-May;24(4):278-85
pubmed: 24633086
Exp Eye Res. 2018 Apr;169:48-53
pubmed: 29374551
Invest Ophthalmol Vis Sci. 2013 Mar 28;54(3):2346-52
pubmed: 23412088
J Glaucoma. 2013 Mar;22(3):219-25
pubmed: 22071557
Invest Ophthalmol Vis Sci. 2011 Jun 16;52(7):4300-6
pubmed: 21372021
Vision Res. 1992 Jul;32(7):1199-209
pubmed: 1455694
Ophthalmology. 2004 Jan;111(1):161-8
pubmed: 14711729
J Glaucoma. 2011 Mar;20(3):133-8
pubmed: 20577113
Curr Opin Ophthalmol. 2006 Apr;17(2):196-202
pubmed: 16552256
Arch Ophthalmol. 1999 May;117(5):573-83
pubmed: 10326953
Doc Ophthalmol. 2013 Dec;127(3):227-38
pubmed: 24126828
J Glaucoma. 2018 Feb;27(2):121-132
pubmed: 29329137
Doc Ophthalmol. 2013 Feb;126(1):1-7
pubmed: 23073702
Transl Vis Sci Technol. 2018 Sep 13;7(5):6
pubmed: 30221072
Cell Tissue Res. 2013 Aug;353(2):287-96
pubmed: 23525754
Optom Vis Sci. 2008 Jun;85(6):386-95
pubmed: 18521020
Curr Opin Ophthalmol. 2016 Mar;27(2):118-24
pubmed: 26720775
Invest Ophthalmol Vis Sci. 2012 Feb 13;53(2):659-63
pubmed: 22247462
Ophthalmology. 2009 Jul;116(7):1271-7
pubmed: 19395086
Ophthalmology. 2005 Jan;112(1):10-9
pubmed: 15629814

Auteurs

Phillip S Gordon (PS)

Mc Knight Vision Research Center, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 1638 NW 10th Ave., Room 101, Miami, FL, 33136, USA.

Maja Kostic (M)

Mc Knight Vision Research Center, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 1638 NW 10th Ave., Room 101, Miami, FL, 33136, USA.

Pedro F Monsalve (PF)

Mc Knight Vision Research Center, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 1638 NW 10th Ave., Room 101, Miami, FL, 33136, USA.

Giacinto Triolo (G)

Mc Knight Vision Research Center, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 1638 NW 10th Ave., Room 101, Miami, FL, 33136, USA.

Luri Golubev (L)

Mc Knight Vision Research Center, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 1638 NW 10th Ave., Room 101, Miami, FL, 33136, USA.

Gabriel Luna (G)

Mc Knight Vision Research Center, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 1638 NW 10th Ave., Room 101, Miami, FL, 33136, USA.

Lori M Ventura (LM)

Mc Knight Vision Research Center, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 1638 NW 10th Ave., Room 101, Miami, FL, 33136, USA.

William J Feuer (WJ)

Mc Knight Vision Research Center, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 1638 NW 10th Ave., Room 101, Miami, FL, 33136, USA.

Vittorio Porciatti (V)

Mc Knight Vision Research Center, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 1638 NW 10th Ave., Room 101, Miami, FL, 33136, USA. vporciatti@med.miami.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH